Injecting drug users will be offered a breakthrough treatment for
hepatitis C as part of a Melbourne study to assess whether treating them
can reduce transmission of the virus in the community.
combination treatment of ledipasvir and sofosbuvir is part of a
promising new generation of direct-acting antiviral drugs, which target
the protein that makes hepatitis C and stops it from replicating.
They have not been widely available outside clinical trials to date in Australia due to their high cost.
Labels: australia, clnical trial, Harvoni, IDU